Key takeaways:

Trials assessing DPP-IV inhibitors, SGLT2 inhibitors and GLP-1s found no increased CV risk for older adults.

Treatment guidance should include recommendations tailored to older populations.

PHILADELPHIA — The global populating is aging, and approximately 29% of people with diabetes worldwide are aged 65 years and older, representing 123 million people, according to a speaker at the Heart in Diabetes CME Conference.

Many adults in this age group have had diabetes for at least 10 years and are at risk for cardiovascular complications such as ischemic heart disease, acute myocardial infarction and cerebrovascular accident, according to Richard E. Pratley, MD, the Samuel E. Crockett Chair in Diabetes Research, medical director of AdventHealth Diabetes Institute and a Heali

See Full Page